Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting ...

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...